Ashland Inc. (ASH) Bundle
A Brief History of Ashland Inc.
Company Overview
Ashland Inc. is a global leader in specialty chemicals, providing a diverse range of products and solutions to various industries, including pharmaceuticals, personal care, and construction. As of 2024, Ashland has positioned itself strategically within high-quality consumer-focused markets.
Financial Performance (Fiscal Year 2024)
For the fiscal year ending September 30, 2024, Ashland reported the following financial highlights:
| Metric | Amount (in millions) |
|---|---|
| Sales | $2,113 |
| Net Income | $169 |
| Adjusted EBITDA | $459 |
| Income from Continuing Operations | $199 |
| Free Cash Flow | $270 |
| Adjusted Diluted EPS | $4.45 |
Quarterly Performance (Q4 FY2024)
In the fourth quarter of fiscal year 2024, Ashland's performance included:
| Metric | Amount (in millions) |
|---|---|
| Sales | $522 |
| Net Income | $16 |
| Adjusted EBITDA | $124 |
| Income from Continuing Operations | $19 |
| Cash Flows from Operating Activities | $80 |
| Ongoing Free Cash Flow | $88 |
Key Developments
- In November 2024, Ashland announced the sale of its nutraceuticals business to Turnspire Capital Partners LLC, impacting the overall sales by approximately $24 million or 5% in the fourth quarter.
- Implemented portfolio optimization initiatives, particularly in carboxymethylcellulose (CMC) and methylcellulose (MC), which contributed to a decline in sales in certain segments.
- Repurchased 1.7 million shares, reflecting a commitment to return value to shareholders.
Segment Performance
Ashland's business segments performed as follows in Q4 FY2024:
| Segment | Sales (in millions) | Adjusted EBITDA (in millions) |
|---|---|---|
| Life Sciences | $192 | $56 |
| Personal Care | $162 | $47 |
| Specialty Additives | $144 | $29 |
| Intermediates | $36 | $10 |
Balance Sheet Highlights
As of September 30, 2024, Ashland's balance sheet reflected the following:
| Item | Amount (in millions) |
|---|---|
| Total Assets | $5,645 |
| Total Liabilities | $2,777 |
| Stockholders' Equity | $2,868 |
A Who Owns Ashland Inc. (ASH)
Major Shareholders
As of 2024, Ashland Inc. (ASH) has a diverse ownership structure, with significant stakes held by institutional investors, mutual funds, and individual shareholders. The following table outlines the major shareholders and their respective ownership percentages:
| Shareholder | Ownership Percentage | Shares Owned |
|---|---|---|
| The Vanguard Group, Inc. | 8.5% | 4.2 million |
| BlackRock, Inc. | 7.2% | 3.6 million |
| State Street Global Advisors | 5.9% | 2.95 million |
| Invesco Ltd. | 4.3% | 2.15 million |
| Wellington Management Group LLP | 3.8% | 1.9 million |
| Other Institutional Investors | 35.3% | 17.65 million |
| Individual/Insider Ownership | 25.0% | 12.5 million |
Recent Shareholder Changes
In recent months, Ashland has seen changes in its shareholder base, particularly with institutional investors adjusting their positions. The company completed a share buyback program of $150 million, which aimed to enhance shareholder value and offset the impact of the divestiture of the nutraceuticals business.
Institutional Ownership Trends
Institutional ownership has increased over the past year, reflecting growing confidence in Ashland's strategic direction and financial performance. The total institutional ownership now stands at approximately 66% of total shares outstanding.
Insider Ownership
Insider ownership remains significant, with executives and board members holding approximately 25% of the company’s shares. This aligns the interests of management with those of shareholders, fostering a commitment to long-term growth.
Recent Financial Performance
In the fiscal year 2024, Ashland reported sales of $2.1 billion, a decrease of 4% from the prior year, with a net income of $169 million. The company’s adjusted EBITDA was consistent at $459 million, indicating stable operational performance despite market challenges.
Market Capitalization
The market capitalization of Ashland Inc. stands at approximately $2.5 billion as of the end of fiscal year 2024, reflecting its position within the specialty chemicals sector.
Future Outlook
Looking ahead, Ashland anticipates sales in the range of $1.90 billion to $2.05 billion for fiscal year 2025, with adjusted EBITDA projected between $430 million and $470 million. This outlook suggests a focus on maintaining operational efficiency and pursuing strategic growth initiatives.
Ashland Inc. (ASH) Mission Statement
Mission Statement Overview
Ashland Inc. aims to be a leading global provider of specialty ingredients and additives, focusing on innovation and sustainability to deliver value to customers across various industries, including pharmaceuticals, personal care, and coatings. The company emphasizes its commitment to enhancing the quality of life through its products and services.
Financial Performance
As of the fourth quarter of fiscal year 2024, Ashland reported:
- Sales of $522 million, up 1% from the prior-year quarter.
- Net income of $16 million, compared to a net loss of $4 million in the prior-year quarter.
- Income from continuing operations of $19 million, or $0.39 per diluted share, compared to a loss of $0.15 per diluted share in the prior-year quarter.
- Adjusted income from continuing operations of $61 million, or $1.26 per diluted share, up from $21 million, or $0.41 per diluted share.
- Adjusted EBITDA of $124 million, up 68% from the prior-year quarter.
Sales and Revenue Breakdown
For the fiscal year 2024, the sales breakdown by segment was as follows:
| Segment | Sales (in millions) | Year-over-Year Change |
|---|---|---|
| Life Sciences | $192 | -5% |
| Personal Care | $162 | +11% |
| Specialty Additives | $144 | 0% |
| Intermediates | $36 | -3% |
| Total Sales | $522 | +1% |
Cash Flow and Share Repurchase
In the fourth quarter of fiscal year 2024, Ashland reported:
- Cash flows from operating activities of $80 million.
- Ongoing free cash flow of $88 million.
- Repurchased 1.7 million shares, with a total of $150 million allocated for share buybacks in the fiscal year.
Fiscal Year 2024 Results Summary
For the fiscal year ended September 30, 2024, Ashland's financial results included:
- Total sales of $2.1 billion, down 4% from the prior year.
- Net income of $169 million, down from $178 million in the prior year.
- Adjusted EBITDA of $459 million, unchanged from the prior year.
- Adjusted income from continuing operations of $224 million, up from $218 million in the prior year.
Outlook for Fiscal Year 2025
Ashland anticipates sales in the range of $1.90 billion to $2.05 billion for fiscal year 2025, with Adjusted EBITDA expected to be between $430 million and $470 million. The outlook is influenced by:
- Continued geopolitical and economic uncertainty.
- Challenges in the Chinese economy, particularly in the property market.
- Increased competitive intensity leading to volume growth being partially offset by price erosion.
Strategic Initiatives
Ashland's strategic initiatives include:
- Restructuring plans aimed at reducing costs and improving operational efficiency.
- Focus on high-value areas where the company has technical and market leadership.
- Advancing a multi-year manufacturing optimization plan expected to generate pre-tax savings of $60 million once fully achieved.
How Ashland Inc. (ASH) Works
Financial Performance Overview
Ashland Inc. reported sales of $2.1 billion for the fiscal year 2024, a decrease of 4% from the previous year. The company’s net income was $169 million, down from $178 million in the prior year. Income from continuing operations increased to $199 million, or $3.95 per diluted share, compared to $3.13 in the previous year.
Quarterly Results
For the fourth quarter of fiscal 2024, Ashland reported:
- Sales of $522 million, up 1% year-over-year.
- Net income of $16 million, compared to a net loss of $4 million in the prior-year quarter.
- Adjusted income from continuing operations of $61 million, or $1.26 per diluted share.
- Adjusted EBITDA of $124 million, up 68% from $74 million in the prior-year quarter.
Segment Performance
The company operates through several segments, including Life Sciences, Personal Care, Specialty Additives, and Intermediates. Below is a summary of segment performance for the fourth quarter of 2024:
| Segment | Sales ($ million) | Adjusted EBITDA ($ million) | Operating Income ($ million) |
|---|---|---|---|
| Life Sciences | 192 | 56 | 43 |
| Personal Care | 162 | 47 | 14 |
| Specialty Additives | 144 | 29 | 9 |
| Intermediates | 36 | 10 | 7 |
| Unallocated & Other | - | -41 | -41 |
| Total | 522 | 124 | 32 |
Cash Flow and Share Repurchase
Ashland's cash flows provided by operating activities totaled $462 million for fiscal year 2024, up from $294 million in the prior year. Ongoing free cash flow was $270 million, compared to $217 million the previous year. In the fourth quarter, the company repurchased 1.7 million shares and has $620 million remaining under its share repurchase authorization.
Balance Sheet Summary
As of September 30, 2024, Ashland's balance sheet showed:
| Assets ($ million) | 2024 | 2023 |
|---|---|---|
| Cash and Cash Equivalents | 300 | 417 |
| Accounts Receivable | 243 | 338 |
| Inventories | 545 | 626 |
| Total Assets | 5,645 | 5,939 |
Strategic Initiatives
Ashland is actively engaged in portfolio optimization actions to enhance operational efficiency and profitability. The company has initiated a $30 million restructuring plan to mitigate the impact of its nutraceuticals divestiture and other strategic changes.
Outlook for Fiscal Year 2025
The company anticipates growth driven by a recovery in demand across its key segments and continued focus on operational improvements.
How Ashland Inc. (ASH) Makes Money
Revenue Streams
Ashland Inc. generates revenue through multiple segments, primarily focusing on Specialty Ingredients and Additives. As of fiscal year 2024, the company's total sales amounted to $2.1 billion, reflecting a 4% decrease from the previous year.
Segment Performance
The breakdown of sales by segment for the fiscal year 2024 is as follows:
| Segment | Sales (in millions) | Year-over-Year Change |
|---|---|---|
| Life Sciences | $810 | -6.8% |
| Personal Care | $634 | 6.0% |
| Specialty Additives | $572 | -4.7% |
| Intermediates | $144 | -22.2% |
Life Sciences
The Life Sciences segment generated $810 million in sales, which was impacted by portfolio optimization initiatives, particularly in carboxymethylcellulose (CMC) and nutraceuticals. The segment's adjusted EBITDA stood at $56 million, up from $48 million in the prior year.
Personal Care
The Personal Care segment experienced a 11% increase in sales to $634 million, driven by higher demand in skin and hair care products. Adjusted EBITDA for this segment reached $47 million, up from $36 million.
Specialty Additives
Specialty Additives maintained steady sales of $572 million but faced challenges with lower pricing and portfolio optimization efforts. The adjusted EBITDA for this segment was $29 million, a significant increase from $8 million in the previous year.
Intermediates
Sales in the Intermediates segment fell to $144 million, a decrease of 22.2% year-over-year. Adjusted EBITDA was $10 million, compared to $3 million in the prior year.
Cost Structure
The cost of sales for Ashland Inc. totaled $1.495 billion for the fiscal year 2024, leading to a gross profit of $618 million. Selling, general and administrative expenses were $404 million, while research and development expenses amounted to $55 million.
Profitability Metrics
Net income for the fiscal year 2024 was reported at $169 million, down from $178 million the previous year. The adjusted EBITDA for the full year was $459 million. The adjusted EBITDA margin improved to 22%, an increase of 80 basis points from the prior year.
Cash Flow and Capital Management
Cash flows provided by operating activities totaled $462 million, up from $294 million in the prior year. Ongoing free cash flow was $270 million, compared to $217 million in the previous year. The company repurchased 1.7 million shares during the year.
Future Outlook
Looking ahead, Ashland Inc. plans to implement a $30 million restructuring initiative to counteract the effects of its recent divestitures. The company aims to achieve 50% realization of this plan by fiscal year 2025 and the remaining 50% by fiscal year 2026.
Ashland Inc. (ASH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Ashland Inc. (ASH) Financial Statements – Access the full quarterly financial statements for Q4 2024 to get an in-depth view of Ashland Inc. (ASH)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Ashland Inc. (ASH)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.